Skip to content
  • Home
  • Journalists
    • Headlines
  • Community
    • Businesses
    • Jobs
    • Learning
    • Marketplace
  • Store
(@)

Novo Nordisk to Replace C.E.O. After Losing Edge in Weight-Loss Drugs

The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market has grown fiercer.

Rebecca Robbins
Author: Rebecca Robbins

Written by

Rebecca Robbins

in

Appointments and Executive Changes, Drugs (Pharmaceuticals), GLP-1 RAs (Drug), Jorgensen, Lars Fruergaard, Novo Nordisk A/S, Ozempic (Drug), Stocks and Bonds
←Why Everything Is ‘Coded’ Now
Who Took the ‘Napalm Girl’ Photo?→

More posts

  • Fiona Cauley & Inevitable Foundation Are Making The Disabled Community “The Main Character” In New Digital Series ‘Talking Sh*t’

  • Lexington Film Office Launches Workforce Development Initiative With Location Managers Guild

  • European grocery chains’ freezers, refrigerators targeted in apparent cyberattacks

  • Newsom proposes $1 billion cap for film and TV tax incentive

About Us


Support Us

Trademark & Copyright 1998 – 2025 · MOSAEC

  • Facebook
  • Instagram
  • LinkedIn
  • YouTube